Lupin inches up on getting tentative approval for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 1174.15, up by 2.35 points or 0.20% from its previous closing of Rs. 1171.80 on the BSE.
The scrip opened at Rs. 1189.95 and has touched a high and low of Rs. 1189.95 and Rs. 1166.35 respectively. So far 4246 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1192.50 on 12-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1192.50 and Rs. 1138.95 respectively. The current market cap of the company is Rs. 53342.91 crore.
The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution, 0.5 g/mL, to market a generic equivalent of Xywav Oral Solution, 0.5 g/mL of Jazz Pharmaceuticals Ireland. This product will be manufactured at Lupin’s Somerset facility in the US.
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch. The net product sales for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution (RLD Xywav) were $958.4 million for the year ending December 2022 and $604.3 million for the first six months of 2023.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
